vs
FEDERAL SIGNAL CORP（FSS）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
UNITED THERAPEUTICS Corpの直近四半期売上が大きい（$790.2M vs $597.1M、FEDERAL SIGNAL CORPの約1.3倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 10.2%、差は35.9%）。FEDERAL SIGNAL CORPの前年同期比売上増加率が高い（26.5% vs 7.4%）。UNITED THERAPEUTICS Corpの直近四半期フリーキャッシュフローが多い（$173.3M vs $89.5M）。過去8四半期でFEDERAL SIGNAL CORPの売上複合成長率が高い（18.5% vs 8.0%）
フェデラルシグナル社は20世紀前半に事業を展開したアメリカ合衆国の鉄道信号機器メーカーで、本社はニューヨーク州オールバニに所在していました。当時の米国鉄道業界では同社の製品が広く採用され、一定の知名度を持っていました。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
FSS vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $597.1M | $790.2M |
| 純利益 | $60.8M | $364.3M |
| 粗利率 | 28.4% | 86.9% |
| 営業利益率 | 14.0% | 45.1% |
| 純利益率 | 10.2% | 46.1% |
| 売上前年比 | 26.5% | 7.4% |
| 純利益前年比 | 21.6% | 20.9% |
| EPS（希薄化後） | $0.99 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $597.1M | $790.2M | ||
| Q3 25 | $555.0M | $799.5M | ||
| Q2 25 | $564.6M | $798.6M | ||
| Q1 25 | $463.8M | $794.4M | ||
| Q4 24 | $472.0M | $735.9M | ||
| Q3 24 | $474.2M | $748.9M | ||
| Q2 24 | $490.4M | $714.9M | ||
| Q1 24 | $424.9M | $677.7M |
| Q4 25 | $60.8M | $364.3M | ||
| Q3 25 | $68.1M | $338.7M | ||
| Q2 25 | $71.4M | $309.5M | ||
| Q1 25 | $46.3M | $322.2M | ||
| Q4 24 | $50.0M | $301.3M | ||
| Q3 24 | $53.9M | $309.1M | ||
| Q2 24 | $60.8M | $278.1M | ||
| Q1 24 | $51.6M | $306.6M |
| Q4 25 | 28.4% | 86.9% | ||
| Q3 25 | 29.1% | 87.4% | ||
| Q2 25 | 30.0% | 89.0% | ||
| Q1 25 | 28.2% | 88.4% | ||
| Q4 24 | 28.1% | 89.7% | ||
| Q3 24 | 29.6% | 88.9% | ||
| Q2 24 | 29.4% | 89.1% | ||
| Q1 24 | 27.3% | 89.2% |
| Q4 25 | 14.0% | 45.1% | ||
| Q3 25 | 16.9% | 48.6% | ||
| Q2 25 | 17.3% | 45.6% | ||
| Q1 25 | 14.2% | 48.2% | ||
| Q4 24 | 14.9% | 48.6% | ||
| Q3 24 | 16.0% | 45.8% | ||
| Q2 24 | 16.5% | 44.7% | ||
| Q1 24 | 12.8% | 52.6% |
| Q4 25 | 10.2% | 46.1% | ||
| Q3 25 | 12.3% | 42.4% | ||
| Q2 25 | 12.6% | 38.8% | ||
| Q1 25 | 10.0% | 40.6% | ||
| Q4 24 | 10.6% | 40.9% | ||
| Q3 24 | 11.4% | 41.3% | ||
| Q2 24 | 12.4% | 38.9% | ||
| Q1 24 | 12.1% | 45.2% |
| Q4 25 | $0.99 | $7.66 | ||
| Q3 25 | $1.11 | $7.16 | ||
| Q2 25 | $1.16 | $6.41 | ||
| Q1 25 | $0.75 | $6.63 | ||
| Q4 24 | $0.80 | $6.23 | ||
| Q3 24 | $0.87 | $6.39 | ||
| Q2 24 | $0.99 | $5.85 | ||
| Q1 24 | $0.84 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $63.7M | $2.9B |
| 総負債低いほど良い | $564.6M | — |
| 株主資本純資産 | $1.4B | $7.1B |
| 総資産 | $2.4B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.41× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $63.7M | $2.9B | ||
| Q3 25 | $54.4M | $2.8B | ||
| Q2 25 | $64.7M | $3.0B | ||
| Q1 25 | $57.5M | $3.3B | ||
| Q4 24 | $91.1M | $3.3B | ||
| Q3 24 | $73.7M | $3.3B | ||
| Q2 24 | $48.6M | $3.0B | ||
| Q1 24 | $48.9M | $2.7B |
| Q4 25 | $564.6M | — | ||
| Q3 25 | $201.2M | — | ||
| Q2 25 | $258.3M | — | ||
| Q1 25 | $266.9M | — | ||
| Q4 24 | $204.4M | — | ||
| Q3 24 | $223.3M | — | ||
| Q2 24 | $248.8M | — | ||
| Q1 24 | $266.8M | — |
| Q4 25 | $1.4B | $7.1B | ||
| Q3 25 | $1.3B | $6.6B | ||
| Q2 25 | $1.3B | $7.2B | ||
| Q1 25 | $1.2B | $6.8B | ||
| Q4 24 | $1.2B | $6.4B | ||
| Q3 24 | $1.1B | $6.1B | ||
| Q2 24 | $1.1B | $5.7B | ||
| Q1 24 | $1.0B | $5.3B |
| Q4 25 | $2.4B | $7.9B | ||
| Q3 25 | $1.9B | $7.4B | ||
| Q2 25 | $1.9B | $7.9B | ||
| Q1 25 | $1.9B | $7.7B | ||
| Q4 24 | $1.8B | $7.4B | ||
| Q3 24 | $1.7B | $7.1B | ||
| Q2 24 | $1.7B | $6.7B | ||
| Q1 24 | $1.7B | $6.5B |
| Q4 25 | 0.41× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.17× | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 0.23× | — | ||
| Q1 24 | 0.26× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $97.2M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $89.5M | $173.3M |
| FCFマージンFCF / 売上 | 15.0% | 21.9% |
| 設備投資強度設備投資 / 売上 | 1.3% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 1.60× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $227.1M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $97.2M | $346.2M | ||
| Q3 25 | $61.1M | $562.1M | ||
| Q2 25 | $59.7M | $191.7M | ||
| Q1 25 | $36.7M | $461.2M | ||
| Q4 24 | $90.6M | $341.2M | ||
| Q3 24 | $68.8M | $377.2M | ||
| Q2 24 | $40.6M | $232.2M | ||
| Q1 24 | $31.3M | $376.5M |
| Q4 25 | $89.5M | $173.3M | ||
| Q3 25 | $54.1M | $351.6M | ||
| Q2 25 | $52.4M | $129.5M | ||
| Q1 25 | $31.1M | $386.3M | ||
| Q4 24 | $82.1M | $254.5M | ||
| Q3 24 | $60.9M | $300.7M | ||
| Q2 24 | $24.8M | $187.1M | ||
| Q1 24 | $22.9M | $338.3M |
| Q4 25 | 15.0% | 21.9% | ||
| Q3 25 | 9.7% | 44.0% | ||
| Q2 25 | 9.3% | 16.2% | ||
| Q1 25 | 6.7% | 48.6% | ||
| Q4 24 | 17.4% | 34.6% | ||
| Q3 24 | 12.8% | 40.2% | ||
| Q2 24 | 5.1% | 26.2% | ||
| Q1 24 | 5.4% | 49.9% |
| Q4 25 | 1.3% | 21.9% | ||
| Q3 25 | 1.3% | 26.3% | ||
| Q2 25 | 1.3% | 7.8% | ||
| Q1 25 | 1.2% | 9.4% | ||
| Q4 24 | 1.8% | 11.8% | ||
| Q3 24 | 1.7% | 10.2% | ||
| Q2 24 | 3.2% | 6.3% | ||
| Q1 24 | 2.0% | 5.6% |
| Q4 25 | 1.60× | 0.95× | ||
| Q3 25 | 0.90× | 1.66× | ||
| Q2 25 | 0.84× | 0.62× | ||
| Q1 25 | 0.79× | 1.43× | ||
| Q4 24 | 1.81× | 1.13× | ||
| Q3 24 | 1.28× | 1.22× | ||
| Q2 24 | 0.67× | 0.83× | ||
| Q1 24 | 0.61× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FSS
| Vehiclesandequipment | $403.4M | 68% |
| Parts | $66.8M | 11% |
| Publicsafetyandsecurityequipment | $62.2M | 10% |
| Rentalincome | $19.0M | 3% |
| Industrialsignalingequipment | $18.2M | 3% |
| Other | $14.9M | 2% |
| Warningsystems | $12.6M | 2% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
